On Thursday, Gilead Sciences, Inc. GILD reported second-quarter revenue of $6.95 billion, beating the consensus of$6.72 billion.Sales increased 5% year over year primarily due to higher product sales in HIV, Liver Disease, and Oncology. Product sales excluding Veklury increased 6% year-over-year to $6.7 billion.Adjusted EPS was$2.01, up from $1.34 a year ago, beating the consensus of$1.60, primarily driven by lower operating expenses and higher revenues.Also Read: Gilead’s $42.5K Priced HIV Drug Could Be ...